Elevated levels of tumor necrosis factor-beta, gamma-interferon, and IL-6 mRNA in Castleman's disease.

Castleman's disease (CD) is a lymphoproliferative disorder characterized by enlarged hyperplastic lymph nodes. CD may be localized or multifocal, and is often associated with signs and symptoms of generalized inflammation. The systemic manifestations of CD have been previously attributed to an overproduction of interleukin-6 (IL-6) by the tumor, although there is evidence that IL-6 is not responsible for all of the symptoms. We describe a 9-year-old boy who developed Castleman's disease with systemic findings of hypochromic microcytic anemia, growth arrest, inflammation, and hyperimmunoglobulinemia. Following surgical resection, all of the symptoms and laboratory abnormalities resolved. Using reverse transcriptase polymerase chain reaction (RT-PCR) analysis of the tumor, we found elevated levels of IL-6 mRNA as expected, but also elevated levels of tumor necrosis factor beta (TNF-beta) and gamma interferon (gamma-IFN) mRNA. Because these cytokines are mediators of immune regulation and inflammation, we propose that TNF-beta and gamma-IFN also play an important role in the pathophysiology of Castleman's disease.

[1]  J. Vilček,et al.  Recent progress in the elucidation of interferon-gamma actions: molecular biology and biological functions. , 1994, International archives of allergy and immunology.

[2]  R. Ware,et al.  Mutations within the Piga gene in patients with paroxysmal nocturnal hemoglobinuria. , 1994, Blood.

[3]  G. Ciliberto,et al.  Development of progressive kidney damage and myeloma kidney in interleukin-6 transgenic mice. , 1994, Blood.

[4]  Scott F. Smith,et al.  Abnormal development of peripheral lymphoid organs in mice deficient in lymphotoxin. , 1994, Science.

[5]  B. Klein,et al.  Brief report: alleviation of systemic manifestations of Castleman's disease by monoclonal anti-interleukin-6 antibody. , 1994, The New England journal of medicine.

[6]  S. Hsu,et al.  Cytokines in malignant lymphomas: review and prospective evaluation. , 1993, Human pathology.

[7]  V. Diehl,et al.  Production of multiple cytokines by Hodgkin's disease derived cell lines , 1992, Hematological oncology.

[8]  A. Gearing,et al.  Expression of ICAM‐1, VCAM‐1 and ELAM‐1 in angiofollicular lymph node hyperplasia (Castleman's disease): evidence for dysplasia of follicular dendritic reticulum cells , 1991, Histopathology.

[9]  J. Diebold,et al.  Interleukin-6 gene expression in Castleman's disease. , 1991, Blood.

[10]  H. Müller-Hermelink,et al.  Cytokine expression in T-cell lymphomas and Hodgkin's disease. Its possible implication in autocrine or paracrine production as a potential basis for neoplastic growth. , 1991, The American journal of pathology.

[11]  R. Ware,et al.  Induction of T cell CD7 gene transcription by nonmitogenic ionomycin-induced transmembrane calcium flux. , 1991, Journal of immunology.

[12]  A. Nienhuis,et al.  Dysregulated interleukin 6 expression produces a syndrome resembling Castleman's disease in mice. , 1990, The Journal of clinical investigation.

[13]  H. Anderson,et al.  Autoimmune cytopenias in Castleman's disease. , 1990, American journal of clinical pathology.

[14]  J. Miyazaki,et al.  IgG1 plasmacytosis in interleukin 6 transgenic mice. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[15]  T. Komori,et al.  Pathogenic significance of interleukin-6 (IL-6/BSF-2) in Castleman's disease , 1989 .

[16]  G. Trinchieri,et al.  Effects of recombinant tumor necrosis factor, lymphotoxin, and immune interferon on proliferation and differentiation of enriched hematopoietic precursor cells. , 1988, Experimental hematology.

[17]  G. Trinchieri,et al.  Tumor necrosis factor and lymphotoxin induce differentiation of human myeloid cell lines in synergy with immune interferon , 1986, The Journal of experimental medicine.

[18]  R. Powell,et al.  Castleman's disease in children. , 1986, Journal of pediatric surgery.

[19]  R. Steinman,et al.  Local and systemic effects of intradermal recombinant interferon-gamma in patients with lepromatous leprosy. , 1986, The New England journal of medicine.

[20]  D. Williams,et al.  The suppressive influences of human tumor necrosis factors on bone marrow hematopoietic progenitor cells from normal donors and patients with leukemia: synergism of tumor necrosis factor and interferon-gamma. , 1986, Journal of immunology.

[21]  W. Daughaday,et al.  Angiomatous lymphoid hamartoma: inhibitory effects on erythropoiesis, growth, and primary hemostasis. , 1981, The Journal of pediatrics.

[22]  B. Castleman,et al.  Hyaline‐vascular and plasma‐cell types of giant lymph node hyperplasia of the mediastinum and other locations , 1972 .

[23]  B. Castleman,et al.  Localized mediastinal lymph‐node hyperplasia resembling thymoma , 1956, Cancer.

[24]  M. Akashi,et al.  Role of lymphotoxin in expression of interleukin 6 in human fibroblasts. Stimulation and regulation. , 1990, The Journal of clinical investigation.

[25]  J. Vilček,et al.  Interleukin 6: a multifunctional cytokine regulating immune reactions and the acute phase protein response. , 1989, Laboratory investigation; a journal of technical methods and pathology.